Annex Lessons Learned Case Studies Below, we highlight valuable insights from our members regarding the challenges faced during project implementation, offering diverse perspectives on the obstacles encountered and, in some cases, the strategies employed to address them. About In 2022, AstraZeneca partnered with the health-tech start-up Qure.Ai to use AI-based software to scan chest X-rays from 5 million patients globally and improve referral and diagnostic pathways for patients with potential lung cancers. This initiative forms part of a broader commitment to pioneering accessible digital solutions in health and education, aiming to stage-shift and improve early-stage detection and diagnosis of diseases. Impact –3.9 million patients screened for high-risk lung nodules (as of December 2024), on track to reach the 5 million commitment –Deployed Qure AI screening technology in 30+ countries globally. –Implemented in over 140 healthcare institutions, with a 50% split between public and private care. Lessons learned1 Early Detection is Critical, but Patient Pathways Must be Comprehensive: Lung cancer is the leading cause of cancer deaths worldwide. Mortality rates are often high due to detection of disease at a later stage, with 10% to 20% five-year survival rate. Early-stage detection and diagnosis can drastically improve patient outcomes. Qure Ai targeted underserved communities in countries like India, the Philippines, and Vietnam to achieve significant impact. Scaling this technology has been successful, but identifying the risk of lung cancer is just the beginning. To drive meaningful impact, it is essential to address the entire patient journey- connecting identification, diagnosis, and treatment to ensure that healthcare systems are transformed into integrated ecosystems that connect the care pathway and ‘close the patient loop. 2 Demonstrating X-Ray Effectiveness Through Evidence-Based Research: Another challenge has been demonstrating the effectiveness of X-ray for risk stratifying high-risk patients, particularly in incidental screenings for lung cancer. To address this, AstraZeneca initiated the CREATE study to build evidence and real- time data for measuring impact.How to connect 1 billion people, and other lessons from the EDISON Alliance’s internet access mission CASE STUDY 1 AstraZeneca: Using AI-based Software to Screen Millions of Patients Globally Lessons Learned Case Studies 1

EDISON Lesson Learned Case Study Annex 2025